Skip to main content

Clinical Trials Using Cyclophosphamide

Review the clinical trials studying cyclophosphamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 376-400 of 416

Epcoritamab with Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Genetically Modified T Cells (UF-KURE-BCMA CAR-T Cells) for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Approved
Location: Roswell Park Cancer Institute, Buffalo, New York
TCRalpha/beta and CD19+ depleted Hematopoietic Stem Cell Transplant from Closely Matched Unrelated Donors or Haploidentical Related donors for Blood Disorders in Children and Young Adults
Status: Approved
Location: 2 locations
211At-OKT10-B10 and Fludarabine Alone or in Combination with Cyclophosphamide and Low-Dose TBI before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Cell Therapy (CIML NK Cells) for the Treatment of Recurrent Myeloid Disease after Donor Blood Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: 3 locations
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: 422 locations
Testing CC-486 (Oral Azacitidine) plus the Standard Drug Therapy in Patients 75 years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 150 locations
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed with Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
Status: Temporarily Closed to Accrual
Location: 9 locations
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Infiltrating Lymphocytes and High-Dose Aldesleukin with or without Autologous Dendritic Cells in Treating Patients with Metastatic Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 83 locations
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Status: Temporarily Closed to Accrual
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Ponatinib in Combination with Venetoclax and Mini-hyper CVD Chemotherapy for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Tazemetostat in Combination with CHOP for Previously Untreated Peripheral T-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 3 locations
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
E7777 to Enhance Regulatory T-Cell Depletion Prior to CAR-T for the Treatment of Relapsed/Refractory B-Cell Lymphomas
Status: Temporarily Closed to Accrual
Location: 2 locations
KSQ-001EX for the Treatment of Patients with Advanced or Metastatic Melanoma, Recurrent Non-Small Cell Lung Carcinoma or Advanced Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab in Combination with Cyclophosphamide, Sorafenib, and Bevacizumab for the Treatment of Recurrent or Refractory Solid Tumors in Pediatric Patients, ANGIO-A Study
Status: Temporarily Closed to Accrual
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Testing the Safety and Feasibility of HER2 CAR T Cells in Patients with Recurrent or Refractory Ependymoma
Status: Temporarily Closed to Accrual
Location: 12 locations
Fludarabine and Cyclophosphamide with or without Rituximab before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Status: Temporarily Closed to Accrual
Location: Roswell Park Cancer Institute, Buffalo, New York
CD4 Chimeric Antigen Receptor T Cell Therapy for Treating Patients with Recurrent or Refractory Acute Myeloid Leukemia
Status: Temporarily Closed to Accrual
Location: 2 locations
Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers
Status: Temporarily Closed to Accrual
Location: Case Comprehensive Cancer Center, Cleveland, Ohio